- Home
- ANL vs NOTV Comparison
ANL vs NOTV Comparison
Compare ANL & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANL | NOTV |
|---|---|---|
| Founded | 2004 | 1974 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.0M | 29.9M |
| IPO Year | 2023 | 1997 |
Fundamental Metrics
Financial Performance| Metric | ANL | NOTV |
|---|---|---|
| Price | $1.05 | $0.80 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 12.5K | ★ 1.6M |
| Earning Date | 11-07-2025 | 12-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $513,024,000.00 |
| Revenue This Year | N/A | $6.26 |
| Revenue Next Year | N/A | $45.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 4.54 |
| 52 Week Low | $1.00 | $0.66 |
| 52 Week High | $2.99 | $6.48 |
Technical Indicators
Market Signals| Indicator | ANL | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 23.81 | 36.67 |
| Support Level | $1.32 | $0.84 |
| Resistance Level | $1.59 | $0.95 |
| Average True Range (ATR) | 0.15 | 0.12 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 1.69 | 39.36 |
Price Performance
Historical ComparisonAbout ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.